News

Find News

Filter articles

Showing 1 to 10 of 1830 results

Italian MEPs attempt to disrupt EMA relocation

EU, Italy16-01-2018

Italian members of the European Parliament are fighting the European Medicines Agency’s relocation to the Netherlands.

CRISPR opposition hearing kicks off at EPO

EPO16-01-2018

Today could play a pivotal role in the CRISPR patent landscape in Europe.

Hoyng Rokh Monegier selects Benoît Strowel as managing partner

16-01-2018

European IP boutique firm Hoyng Rokh Monegier has announced that Benoît Strowel will succeed Willem Hoyng as managing partner.

Settlement reached in long-running tissue patent dispute

15-01-2018

Biopharmaceutical company MiMedx Group has settled a long-standing patent infringement dispute with the Musculoskeletal Transplant Foundation, Medline Industries and Liventa Bioscience.

Nuvo Pharmaceuticals acquires head lice removal treatment

Canada, US15-01-2018

Healthcare firm Nuvo Pharmaceuticals has announced the acquisition of Resultz from US company Piedmont Pharmaceuticals.

US identifies shortcomings in China’s IP pharma sector

15-01-2018

The US Department of Commerce (DOC) has said that there are “shortcomings” in China’s IP rights when it comes to the country’s pharmaceutical sector.

Regeneron forms consortium to fund exome sequencing

UK12-01-2018

Regeneron Pharmaceuticals has formed a consortium with five other companies to fund the generation of exome sequence data from 500,000 volunteers in the UK.

Teva and Alder sign deal to overcome antibodies dispute

11-01-2018

Israel-based Teva Pharmaceuticals has signed a global licence agreement with Alder BioPharmaceuticals.

Allergan tells Federal Circuit Restasis patents are valid

11-01-2018

Allergan and the Native American tribe that acquired Allergan’s patents for Restasis have told the US Court of Appeals for the Federal Circuit that patents covering the dry eye treatment are valid.

Federal Circuit rejects Monsanto’s soybean appeal

11-01-2018

The US Court of Appeals for the Federal Circuit has confirmed that claims within a patent relating to genetically modified soybeans are invalid due to anticipation and obviousness.

Showing 1 to 10 of 1830 results

LSIPR